Audra Moran on the Ovarian Cancer National Conference

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Quality of life may temporarily worsen after patients with myeloma receive stem cell transplants, said an expert at the Educated Patient® Multiple Myeloma Summit.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Seeing a young man ringing the bell surrounded by family reminded me of the incredible support I received during ovarian cancer, too.